当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
TAS-102 in metastatic colorectal cancer
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-12-14 , DOI: 10.1016/s1470-2045(17)30927-0
Talha Khan Burki

A new study has found that trifluridine/tipiracil (TAS-102)significantly increases overall survival compared with that for placebo in Asian patients with advanced colorectal cancer, irrespective of whether they have been exposed to biological therapy.

中文翻译:

TAS-102在转移性大肠癌中的应用

一项新的研究发现,与亚洲的晚期大肠癌患者相比,三氟吡啶/替普拉西酯(TAS-102)显着提高了总生存率,而与他们是否接受过生物疗法无关。
更新日期:2017-12-31
down
wechat
bug